The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Sitagliptin Hydrochloride Oral · SITAGLIPTIN 25 mg/mL · Solution · Oral · Azurity Pharmaceuticals, Inc.
NDC 24338-0017-01 · 1 BOTTLE in 1 CARTON / 120 mL in 1 BOTTLE · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
| Type | Number / code | Expires |
|---|---|---|
| patent | 12295953 | Oct 23, 2040 |
| patent | 11944621 | Oct 23, 2040 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Azurity Pharmaceuticals, Inc. | SITAGLIPTIN 25 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Brynovin — NDC 24338-0017-01," retrieved September 3, 2026, https://drugdashboards.com/drug/24338001701.
Free to cite with attribution — see how the data is put together.